mmahomed2
- Mar 10, 2018
- 1 min read

Orthopaedic Research Society

Valitor presented the its first preclinical data demonstration the potential of our anti-inflammatory product to treat arthritis at the Orthopaedic Research Society conference in New Orleans, LA. This report demonstrated a substantial increase intra-articular half-life for our lead anti-inflammatory compound compared an equivalent unconjugated antibody. These data demonstrate how our technology to enhance the ability of anti-inflammatory antibodies to treat a variety of joint disorders.

Recent Posts

See All

Series A financing

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Phase I SBIR grant from the National Cancer Institute

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammat